Evaluation of Light's criteria in cytologically proved malignant pleural effusions.


Journal

Minerva medica
ISSN: 1827-1669
Titre abrégé: Minerva Med
Pays: Italy
ID NLM: 0400732

Informations de publication

Date de publication:
Feb 2023
Historique:
pubmed: 29 6 2021
medline: 23 2 2023
entrez: 28 6 2021
Statut: ppublish

Résumé

Malignant pleural effusions are usually described as exudates. However, several studies have determined a high incidence of cytologically proved malignant effusions in transudates. The study aims to determine the compliance of cytologically proved malignant pleural effusions with Light's Criteria and to assess when it is necessary to perform more studies in transudates. We have retrospectively reviewed all the cytologically positive effusions at our institution over six years. Biochemical characteristics were recorded, and Light's criteria were determined for each effusion. We analyzed the effusions' compliance with the criteria and determined whether its primary tumor or the presence of cirrhosis, acute kidney injury or congestive heart failure could interfere in the criteria being met. Overall, 224 patients presented malignant pleural effusions with biochemical pleural fluid analysis. Two (0.9%) were transudative effusions and two hundred and twenty-two (99.1%) were exudative effusions. Lung carcinoma, breast carcinoma and ovarian carcinoma were the most frequent primary tumors. One hundred and two (45.94%) patients met three Light criteria, 77 (34.68%) patients met two criteria and 43 (19.36%) met one criterion. Both patients with transudative malignant pleural effusions presented concomitant malignant ascites. Malignant transudative pleural effusions were 0.9% of our patients. We found no relation between transudative malignant effusions and the presence of cirrhosis, acute kidney injury or congestive heart failure, or the type of tumor. We found no difference between the tumor type and the distribution of Light's criteria met.

Sections du résumé

BACKGROUND BACKGROUND
Malignant pleural effusions are usually described as exudates. However, several studies have determined a high incidence of cytologically proved malignant effusions in transudates. The study aims to determine the compliance of cytologically proved malignant pleural effusions with Light's Criteria and to assess when it is necessary to perform more studies in transudates.
METHODS METHODS
We have retrospectively reviewed all the cytologically positive effusions at our institution over six years. Biochemical characteristics were recorded, and Light's criteria were determined for each effusion. We analyzed the effusions' compliance with the criteria and determined whether its primary tumor or the presence of cirrhosis, acute kidney injury or congestive heart failure could interfere in the criteria being met.
RESULTS RESULTS
Overall, 224 patients presented malignant pleural effusions with biochemical pleural fluid analysis. Two (0.9%) were transudative effusions and two hundred and twenty-two (99.1%) were exudative effusions. Lung carcinoma, breast carcinoma and ovarian carcinoma were the most frequent primary tumors. One hundred and two (45.94%) patients met three Light criteria, 77 (34.68%) patients met two criteria and 43 (19.36%) met one criterion. Both patients with transudative malignant pleural effusions presented concomitant malignant ascites.
CONCLUSIONS CONCLUSIONS
Malignant transudative pleural effusions were 0.9% of our patients. We found no relation between transudative malignant effusions and the presence of cirrhosis, acute kidney injury or congestive heart failure, or the type of tumor. We found no difference between the tumor type and the distribution of Light's criteria met.

Identifiants

pubmed: 34180643
pii: S0026-4806.21.07586-8
doi: 10.23736/S0026-4806.21.07586-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-42

Auteurs

Samuel Garcia-Reina (S)

Department of Thoracic Surgery and Thorax Clinic Institute, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona College of Medicine, Badalona, Spain - sgreina@gmail.com.

Esther Fernández (E)

Department of Thoracic Surgery and Thorax Clinic Institute, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona College of Medicine, Badalona, Spain.

Alba Hernandez (A)

Department of Pathology, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona College of Medicine, Badalona, Spain.

Marta Lacambra (M)

Department of Anaesthesiology, Hospital Universitari of Vic, Vic, Spain.

Pedro E Lopez DE Castro (PE)

Department of Thoracic Surgery and Thorax Clinic Institute, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona College of Medicine, Badalona, Spain.

Antoni Rosell (A)

Thorax Clinic Institute, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona College of Medicine, Badalona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH